<DOC>
	<DOCNO>NCT01082887</DOCNO>
	<brief_summary>The main objective study evaluate clinical biologic toxicity cell therapy adoptive transfer TIL combination intra-tumoral injection Ad-INFg .</brief_summary>
	<brief_title>A Study Immunotherapy With TIL ( Tumor Infiltrating Lymphocytes ) Combination With Intra-tumoral Injections Interferon Gamma-adenovirus ( Ad-IFNg ) Patients With Stage IIIc Stage IV Metastatic Melanoma ( AJCC ) ( Protocol TIL-Ad-INFg )</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Adenoviridae Infections</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>Pre Male female patient ≥ 18 ≤ 75 year age Patients must sign informed consent A negative pregnancy test woman childbearing potential Patients stage IIIc/IV metastatic melanoma ( AJCC 6th edition ) nodal relapse , transit metastasis , unresectable cutaneous metastasis , visceral metastasis except bone brain metastasis Presence least one lesion accessible intratumoral injection AdIFNg A negative brain scan , eliminate brain metastasis ECOG performance status 02 Adequate bonemarrow reserve , renal function hepatic function assess standard laboratory criterion Subjects affiliate appropriate social security system Negative viral serology ( HIV ½ , p24 Ag , HTLV 1 / 2 , B C hepatitis ) For female : patient pregnant lactate use contraception prove negative pregnancy test Positive viral serology HIV ½ , p24 Ag , HTLV 1 / 2 B C hepatitis History current manifestation severe progressive heart disease ( congestive heart failure , coronary artery disease , uncontrolled arterial hypertension , serious rhythm disorder ECG sign previous myocardial infarction ) Any serious illness , acute chronic , e.g . active infection require antibiotic , bleed disorder condition require concomitant medication allow study Presence second active cancer except situ cervical cancer skin carcinoma Intercurrent disease require corticosteroid treatment treatment interferonα Any autoimmune disease include active diabetes mellitus immunodeficiency . Vitiligo exclusion criterion Uncontrolled thyroid dysfunction Concurrently participation biomedical research ( drug radiotherapy ) within month precede inclusion Metastatic lymph node stage alone indication lymphadenectomy Brain bone metastasis discover radiological examination inclusion assessment Surgically resectable metastasis Ocular melanoma More one line chemotherapy treatment melanoma Chemotherapy , immunotherapy radiotherapy within 4 week baseline ( 6 week nitrosoureas mitomycin C ) Contraindication use vasopressor agent Treatment molecule premarketing development whose development finish less 4 week</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Immunotherapy TIL ( Tumor Infiltrating Lymphocytes )</keyword>
	<keyword>Intra-tumoral injection</keyword>
	<keyword>Interferon gamma-adenovirus ( Ad-IFNg )</keyword>
	<keyword>Metastatic melanoma</keyword>
	<keyword>A stage IIIc/IV metastatic melanoma nodal relapse</keyword>
	<keyword>transit metastasis</keyword>
	<keyword>cutaneous unresectable metastasis</keyword>
	<keyword>visceral metastasis</keyword>
</DOC>